News
ZYME
30.81
+3.98%
1.18
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
NASDAQ · 5h ago
Zymeworks Reports Quarterly Results, Raises 2026 Guidance
TipRanks · 6h ago
*Zymeworks 3Q Net $173.7M >ZYME
Dow Jones · 7h ago
Press Release: Zymeworks Provides Corporate -2-
Dow Jones · 7h ago
Weekly Report: what happened at ZYME last week (1102-1106)?
Weekly Report · 18h ago
Zymeworks Can No Longer Hide Behind Its Partners' Milestones
Barchart · 3d ago
Zymeworks (ZYME) Stock Seems Fully Priced On Its 336% Run
Simply Wall St · 4d ago
Is Zymeworks (ZYME) A Bargain On New ZW191 Data And The Roche Deal?
Simply Wall St · 5d ago
Learn Why The Bull Case For Zymeworks Stock Could Change Following Phase 1 Ovarian Cancer Data
Simply Wall St · 11/03 00:35
Weekly Report: what happened at ZYME last week (1026-1030)?
Weekly Report · 11/02 10:04
Zymeworks (ZYME) Receives a Buy from Truist Financial
TipRanks · 10/30 02:26
Zymeworks Price Target Raised to $35.00/Share From $34.00 by Truist Securities
Dow Jones · 10/28 17:29
Zymeworks Is Maintained at Buy by Truist Securities
Dow Jones · 10/28 17:29
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35
Benzinga · 10/28 17:18
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Benitec Biopharma (BNTC)
TipRanks · 10/28 15:11
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 10/28 05:20
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
TipRanks · 10/26 14:38
Weekly Report: what happened at ZYME last week (1019-1023)?
Weekly Report · 10/26 10:04
ZW191 Trial Data Could Be A Big Test For Zymeworks Stock
Simply Wall St · 10/25 23:37
Zymeworks presents new clinical data on Phase 1 study of ZW191
TipRanks · 10/25 20:15
More
Webull provides a variety of real-time ZYME stock news. You can receive the latest news about Zymeworks through multiple platforms. This information may help you make smarter investment decisions.
About ZYME
Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528.